Posaconazole oral suspension 40 mg/mL
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fungal Infections
Conditions
Fungal Infections
Trial Timeline
Feb 1, 2012 โ Nov 1, 2013
NCT ID
NCT01436578About Posaconazole oral suspension 40 mg/mL
Posaconazole oral suspension 40 mg/mL is a pre-clinical stage product being developed by Merck for Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01436578. Target conditions include Fungal Infections.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01436578 | Pre-clinical | Completed |
Competing Products
20 competing products in Fungal Infections